The New Biotech IPO Math
Executive Summary
Biotech IPOs are setting record valuations--the current deals average three-to-five times the previous average IPO valuations. Behind the hysteria: a new math which values biotechs not on some discount to future earnings, but on their ability to dominate new and important pharmaceutical business areas and thereby create new monopolies.